Gilead Sciences Inc announced on Friday that additional data from a late-stage study showed its antiviral remdesivir improved death rates as well the conditions of severely ill coronavirus patients. In a new study, nearly 75% of severely ill coronavirus patients treated with remdesivir recovered compared to 59% not given the drug. Pictured: Ampules of remdesivir for patients infected with coronavirus at the University hospital in Essen, Germany, June 3Only 7.6% of remdesivir-treated patients died compared to 12.5% off those who received standard of care. By Day 14, 74.4 percent of those treated with remdesivir recovered compared to 59 percent not given the drug. Additionally, only 7.6 percent of remdesivir-treated patients died compared to 12.5 percent of those who received standard of care.

Source: Daily Mail July 10, 2020 19:35 UTC